Biotech Watch List: GTx (NASDAQ:GTXI), Anacor Pharmaceuticals Inc (NASDAQ:ANAC), 22nd Century Group Inc (NYSEMKT:XXII), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)



GTX Inc. (NASDAQ:GTXI) was a big mover last session, as its shares rose over 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the trend for the company since Apr 7, as the stock is now trading above the volatile price range of $1.32 to $1.50. GTx, Inc. (NASDAQ:GTXI) stock performance was -3.33% in last session and finished the day at $1.45. Traded volume was 353,850.00million shares in the last session and the average volume of the stock remained 541.94K shares. The beta of the stock remained 1.19. GTx, Inc. (NASDAQ:GTXI) insider ownership is 43.60%.

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company’s President and Chief Executive Officer, will provide a company overview at Deutsche Bank’s 39th Annual Health Care Conference on Thursday, May 8, 2014 at 10:40 a.m. ET in Boston, Massachusetts. Anacor Pharmaceuticals Inc (NASDAQ:ANAC) rose 6.26 percent to $17.65 Monday on volume of 402,646.00million shares. The intra-day range of the stock was $16.28 to $17.87. Anacor Pharmaceuticals Inc (NASDAQ:ANAC) has a market capitalization of $738.45million.

One of the Purple Palace’s offerings will come from Emmy-nominated director Paul Feig, who was behind cult TV show Freaks and Geeks and popular comedy movieBridesmaids. Other Space will be a galactic adventure set in the early 22nd century Group Inc (NYSEMKT:XXII) and featuring a group of misfits that discovers an alternate universe. 22nd Century Group Inc (NYSEMKT:XXII)’s stock on May 5, 2014 reported a decrease of -4.64% to the closing price of $2.67. Its fifty two weeks range is $0.52 -$6.36. The total market capitalization recorded $155.53million. The overall volume in the last trading session was 452,438.00million shares. In its share capital, XXII has 58.68million outstanding shares.

Trade-Ideas LLC identified Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) as a “perilous reversal” (up big yesterday but down big today) candidate. TheStreet Quant Ratings rates Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) as a sell. On Monday, shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) dropped -3.24% to close the day at $14.04. Company return on investment (ROI) is -46.30% and its monthly performance is recorded as -16.18%. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) quarterly revenue growth is 26.37%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone